PINP: A serum biomarker of bone formation in the rat
Abstract Serum PINP has emerged as a reliable marker of bone turnover in humans and is routinely used to monitor bone formation. However, the effects of PTH (1–34) on bone turnover have not been evaluated following short-term treatment. We present data demonstrating that PINP is an early serum bioma...
Gespeichert in:
| Veröffentlicht in: | Bone (New York, N.Y.) N.Y.), 2007-04, Vol.40 (4), p.1103-1109 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1109 |
|---|---|
| container_issue | 4 |
| container_start_page | 1103 |
| container_title | Bone (New York, N.Y.) |
| container_volume | 40 |
| creator | Hale, L.V Galvin, R.J. Sells Risteli, J Ma, Y.L Harvey, A.K Yang, X Cain, R.L Zeng, Q Frolik, C.A Sato, M Schmidt, A.L Geiser, A.G |
| description | Abstract Serum PINP has emerged as a reliable marker of bone turnover in humans and is routinely used to monitor bone formation. However, the effects of PTH (1–34) on bone turnover have not been evaluated following short-term treatment. We present data demonstrating that PINP is an early serum biomarker in the rat for assessing bone anabolic activity in response to treatment with PTH (1–38). Rat serum PINP levels were found to increase following as few as 6 days of treatment with PTH (1–38) and these increases paralleled expression of genes associated with bone formation, as well as, later increases in BMD. Additionally, PINP levels were unaffected by treatment with an antiresorptive bisphosphonate. PINP may be used to detect PTH-induced early bone formation in the rat and may be more generally applicable for preclinical testing of potential bone anabolic drugs. |
| doi_str_mv | 10.1016/j.bone.2006.11.027 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70269609</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S8756328206008593</els_id><sourcerecordid>70269609</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-29993de60c3cfd57bda628bca8a5f6a2aeb56625d8ba4a71c6a24eb5bb52638d3</originalsourceid><addsrcrecordid>eNqFkU9rFTEUxYMo9rX2C7iQ2ehupjfJy58RKZRitVC0oF2HJHMH8zozqcmM0G9vhveg4MKuApffOTf3HELeUmgoUHm2a1ycsGEAsqG0AaZekA3VitdMSf6SbLQSsuZMsyNynPMOAHir6GtyRBUTWjDYkO3t9bfbj9VFlTEtY-VCHG26x1TFvlrdqz6m0c4hTlWYqvkXVsnOb8ir3g4ZTw_vCbm7-vzz8mt98_3L9eXFTe23CuaatW3LO5Tgue87oVxnJdPOW21FLy2z6ISUTHTa2a1V1JfZtsycE0xy3fET8mHv-5Di7wXzbMaQPQ6DnTAu2ShgspXQPgvSVkqp1QqyPehTzDlhbx5SKBc_GgpmDdXszHq2WUM1lJoSahG9O7gvbsTuSXJIsQDvD4DN3g59spMP-YnTUvFyUOE-7Tksof0JmEz2ASePXUjoZ9PF8P9_nP8j90OYQtl4j4-Yd3FJU6nDUJOZAfNjrX9tHySAFi3nfwG4BKhS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19666879</pqid></control><display><type>article</type><title>PINP: A serum biomarker of bone formation in the rat</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hale, L.V ; Galvin, R.J. Sells ; Risteli, J ; Ma, Y.L ; Harvey, A.K ; Yang, X ; Cain, R.L ; Zeng, Q ; Frolik, C.A ; Sato, M ; Schmidt, A.L ; Geiser, A.G</creator><creatorcontrib>Hale, L.V ; Galvin, R.J. Sells ; Risteli, J ; Ma, Y.L ; Harvey, A.K ; Yang, X ; Cain, R.L ; Zeng, Q ; Frolik, C.A ; Sato, M ; Schmidt, A.L ; Geiser, A.G</creatorcontrib><description>Abstract Serum PINP has emerged as a reliable marker of bone turnover in humans and is routinely used to monitor bone formation. However, the effects of PTH (1–34) on bone turnover have not been evaluated following short-term treatment. We present data demonstrating that PINP is an early serum biomarker in the rat for assessing bone anabolic activity in response to treatment with PTH (1–38). Rat serum PINP levels were found to increase following as few as 6 days of treatment with PTH (1–38) and these increases paralleled expression of genes associated with bone formation, as well as, later increases in BMD. Additionally, PINP levels were unaffected by treatment with an antiresorptive bisphosphonate. PINP may be used to detect PTH-induced early bone formation in the rat and may be more generally applicable for preclinical testing of potential bone anabolic drugs.</description><identifier>ISSN: 8756-3282</identifier><identifier>EISSN: 1873-2763</identifier><identifier>DOI: 10.1016/j.bone.2006.11.027</identifier><identifier>PMID: 17258520</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Animals ; Biological and medical sciences ; Biomarkers - blood ; Bisphosphonate ; Bone formation ; Bone Remodeling - drug effects ; Bone Remodeling - genetics ; Bone Remodeling - physiology ; Bones, joints and connective tissue. Antiinflammatory agents ; Carboxypeptidases - genetics ; CCN Intercellular Signaling Proteins ; Collagen - genetics ; Collagen Type I ; Female ; Gene Expression - drug effects ; Humans ; Medical sciences ; Oncogene Proteins - genetics ; Orthopedics ; Osteocalcin - genetics ; Osteogenesis - drug effects ; Osteogenesis - genetics ; Osteogenesis - physiology ; Ovariectomy ; Parathyroid Hormone - pharmacology ; Peptide Fragments - blood ; Peptide Fragments - pharmacology ; Pharmacology. Drug treatments ; PINP ; Procollagen - blood ; Proto-Oncogene Proteins ; PTH ; Rats ; Rats, Sprague-Dawley ; Recombinant Proteins - pharmacology ; RNA, Messenger - genetics ; RNA, Messenger - metabolism ; Serum biomarker</subject><ispartof>Bone (New York, N.Y.), 2007-04, Vol.40 (4), p.1103-1109</ispartof><rights>Elsevier Inc.</rights><rights>2006 Elsevier Inc.</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-29993de60c3cfd57bda628bca8a5f6a2aeb56625d8ba4a71c6a24eb5bb52638d3</citedby><cites>FETCH-LOGICAL-c470t-29993de60c3cfd57bda628bca8a5f6a2aeb56625d8ba4a71c6a24eb5bb52638d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S8756328206008593$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18673638$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17258520$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hale, L.V</creatorcontrib><creatorcontrib>Galvin, R.J. Sells</creatorcontrib><creatorcontrib>Risteli, J</creatorcontrib><creatorcontrib>Ma, Y.L</creatorcontrib><creatorcontrib>Harvey, A.K</creatorcontrib><creatorcontrib>Yang, X</creatorcontrib><creatorcontrib>Cain, R.L</creatorcontrib><creatorcontrib>Zeng, Q</creatorcontrib><creatorcontrib>Frolik, C.A</creatorcontrib><creatorcontrib>Sato, M</creatorcontrib><creatorcontrib>Schmidt, A.L</creatorcontrib><creatorcontrib>Geiser, A.G</creatorcontrib><title>PINP: A serum biomarker of bone formation in the rat</title><title>Bone (New York, N.Y.)</title><addtitle>Bone</addtitle><description>Abstract Serum PINP has emerged as a reliable marker of bone turnover in humans and is routinely used to monitor bone formation. However, the effects of PTH (1–34) on bone turnover have not been evaluated following short-term treatment. We present data demonstrating that PINP is an early serum biomarker in the rat for assessing bone anabolic activity in response to treatment with PTH (1–38). Rat serum PINP levels were found to increase following as few as 6 days of treatment with PTH (1–38) and these increases paralleled expression of genes associated with bone formation, as well as, later increases in BMD. Additionally, PINP levels were unaffected by treatment with an antiresorptive bisphosphonate. PINP may be used to detect PTH-induced early bone formation in the rat and may be more generally applicable for preclinical testing of potential bone anabolic drugs.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Bisphosphonate</subject><subject>Bone formation</subject><subject>Bone Remodeling - drug effects</subject><subject>Bone Remodeling - genetics</subject><subject>Bone Remodeling - physiology</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Carboxypeptidases - genetics</subject><subject>CCN Intercellular Signaling Proteins</subject><subject>Collagen - genetics</subject><subject>Collagen Type I</subject><subject>Female</subject><subject>Gene Expression - drug effects</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Oncogene Proteins - genetics</subject><subject>Orthopedics</subject><subject>Osteocalcin - genetics</subject><subject>Osteogenesis - drug effects</subject><subject>Osteogenesis - genetics</subject><subject>Osteogenesis - physiology</subject><subject>Ovariectomy</subject><subject>Parathyroid Hormone - pharmacology</subject><subject>Peptide Fragments - blood</subject><subject>Peptide Fragments - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>PINP</subject><subject>Procollagen - blood</subject><subject>Proto-Oncogene Proteins</subject><subject>PTH</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Recombinant Proteins - pharmacology</subject><subject>RNA, Messenger - genetics</subject><subject>RNA, Messenger - metabolism</subject><subject>Serum biomarker</subject><issn>8756-3282</issn><issn>1873-2763</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9rFTEUxYMo9rX2C7iQ2ehupjfJy58RKZRitVC0oF2HJHMH8zozqcmM0G9vhveg4MKuApffOTf3HELeUmgoUHm2a1ycsGEAsqG0AaZekA3VitdMSf6SbLQSsuZMsyNynPMOAHir6GtyRBUTWjDYkO3t9bfbj9VFlTEtY-VCHG26x1TFvlrdqz6m0c4hTlWYqvkXVsnOb8ir3g4ZTw_vCbm7-vzz8mt98_3L9eXFTe23CuaatW3LO5Tgue87oVxnJdPOW21FLy2z6ISUTHTa2a1V1JfZtsycE0xy3fET8mHv-5Di7wXzbMaQPQ6DnTAu2ShgspXQPgvSVkqp1QqyPehTzDlhbx5SKBc_GgpmDdXszHq2WUM1lJoSahG9O7gvbsTuSXJIsQDvD4DN3g59spMP-YnTUvFyUOE-7Tksof0JmEz2ASePXUjoZ9PF8P9_nP8j90OYQtl4j4-Yd3FJU6nDUJOZAfNjrX9tHySAFi3nfwG4BKhS</recordid><startdate>20070401</startdate><enddate>20070401</enddate><creator>Hale, L.V</creator><creator>Galvin, R.J. Sells</creator><creator>Risteli, J</creator><creator>Ma, Y.L</creator><creator>Harvey, A.K</creator><creator>Yang, X</creator><creator>Cain, R.L</creator><creator>Zeng, Q</creator><creator>Frolik, C.A</creator><creator>Sato, M</creator><creator>Schmidt, A.L</creator><creator>Geiser, A.G</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>20070401</creationdate><title>PINP: A serum biomarker of bone formation in the rat</title><author>Hale, L.V ; Galvin, R.J. Sells ; Risteli, J ; Ma, Y.L ; Harvey, A.K ; Yang, X ; Cain, R.L ; Zeng, Q ; Frolik, C.A ; Sato, M ; Schmidt, A.L ; Geiser, A.G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-29993de60c3cfd57bda628bca8a5f6a2aeb56625d8ba4a71c6a24eb5bb52638d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Bisphosphonate</topic><topic>Bone formation</topic><topic>Bone Remodeling - drug effects</topic><topic>Bone Remodeling - genetics</topic><topic>Bone Remodeling - physiology</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Carboxypeptidases - genetics</topic><topic>CCN Intercellular Signaling Proteins</topic><topic>Collagen - genetics</topic><topic>Collagen Type I</topic><topic>Female</topic><topic>Gene Expression - drug effects</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Oncogene Proteins - genetics</topic><topic>Orthopedics</topic><topic>Osteocalcin - genetics</topic><topic>Osteogenesis - drug effects</topic><topic>Osteogenesis - genetics</topic><topic>Osteogenesis - physiology</topic><topic>Ovariectomy</topic><topic>Parathyroid Hormone - pharmacology</topic><topic>Peptide Fragments - blood</topic><topic>Peptide Fragments - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>PINP</topic><topic>Procollagen - blood</topic><topic>Proto-Oncogene Proteins</topic><topic>PTH</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Recombinant Proteins - pharmacology</topic><topic>RNA, Messenger - genetics</topic><topic>RNA, Messenger - metabolism</topic><topic>Serum biomarker</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hale, L.V</creatorcontrib><creatorcontrib>Galvin, R.J. Sells</creatorcontrib><creatorcontrib>Risteli, J</creatorcontrib><creatorcontrib>Ma, Y.L</creatorcontrib><creatorcontrib>Harvey, A.K</creatorcontrib><creatorcontrib>Yang, X</creatorcontrib><creatorcontrib>Cain, R.L</creatorcontrib><creatorcontrib>Zeng, Q</creatorcontrib><creatorcontrib>Frolik, C.A</creatorcontrib><creatorcontrib>Sato, M</creatorcontrib><creatorcontrib>Schmidt, A.L</creatorcontrib><creatorcontrib>Geiser, A.G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Bone (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hale, L.V</au><au>Galvin, R.J. Sells</au><au>Risteli, J</au><au>Ma, Y.L</au><au>Harvey, A.K</au><au>Yang, X</au><au>Cain, R.L</au><au>Zeng, Q</au><au>Frolik, C.A</au><au>Sato, M</au><au>Schmidt, A.L</au><au>Geiser, A.G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PINP: A serum biomarker of bone formation in the rat</atitle><jtitle>Bone (New York, N.Y.)</jtitle><addtitle>Bone</addtitle><date>2007-04-01</date><risdate>2007</risdate><volume>40</volume><issue>4</issue><spage>1103</spage><epage>1109</epage><pages>1103-1109</pages><issn>8756-3282</issn><eissn>1873-2763</eissn><abstract>Abstract Serum PINP has emerged as a reliable marker of bone turnover in humans and is routinely used to monitor bone formation. However, the effects of PTH (1–34) on bone turnover have not been evaluated following short-term treatment. We present data demonstrating that PINP is an early serum biomarker in the rat for assessing bone anabolic activity in response to treatment with PTH (1–38). Rat serum PINP levels were found to increase following as few as 6 days of treatment with PTH (1–38) and these increases paralleled expression of genes associated with bone formation, as well as, later increases in BMD. Additionally, PINP levels were unaffected by treatment with an antiresorptive bisphosphonate. PINP may be used to detect PTH-induced early bone formation in the rat and may be more generally applicable for preclinical testing of potential bone anabolic drugs.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>17258520</pmid><doi>10.1016/j.bone.2006.11.027</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 8756-3282 |
| ispartof | Bone (New York, N.Y.), 2007-04, Vol.40 (4), p.1103-1109 |
| issn | 8756-3282 1873-2763 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70269609 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Biological and medical sciences Biomarkers - blood Bisphosphonate Bone formation Bone Remodeling - drug effects Bone Remodeling - genetics Bone Remodeling - physiology Bones, joints and connective tissue. Antiinflammatory agents Carboxypeptidases - genetics CCN Intercellular Signaling Proteins Collagen - genetics Collagen Type I Female Gene Expression - drug effects Humans Medical sciences Oncogene Proteins - genetics Orthopedics Osteocalcin - genetics Osteogenesis - drug effects Osteogenesis - genetics Osteogenesis - physiology Ovariectomy Parathyroid Hormone - pharmacology Peptide Fragments - blood Peptide Fragments - pharmacology Pharmacology. Drug treatments PINP Procollagen - blood Proto-Oncogene Proteins PTH Rats Rats, Sprague-Dawley Recombinant Proteins - pharmacology RNA, Messenger - genetics RNA, Messenger - metabolism Serum biomarker |
| title | PINP: A serum biomarker of bone formation in the rat |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T03%3A09%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PINP:%20A%20serum%20biomarker%20of%20bone%20formation%20in%20the%20rat&rft.jtitle=Bone%20(New%20York,%20N.Y.)&rft.au=Hale,%20L.V&rft.date=2007-04-01&rft.volume=40&rft.issue=4&rft.spage=1103&rft.epage=1109&rft.pages=1103-1109&rft.issn=8756-3282&rft.eissn=1873-2763&rft_id=info:doi/10.1016/j.bone.2006.11.027&rft_dat=%3Cproquest_cross%3E70269609%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19666879&rft_id=info:pmid/17258520&rft_els_id=S8756328206008593&rfr_iscdi=true |